NBIX - Neurocrine Biosciences (NBIX) Q4 2023 Earnings Call Transcript
2024-02-07 12:58:06 ET
Neurocrine Biosciences Inc. (NBIX)
Q4 2023 Earnings Conference Call
February 7, 2024 8:00 am ET
Company Participants
Kevin Gorman - Chief Executive Officer
Matt Abernethy - Chief Financial Officer
Eric Benevich - Chief Commercial Officer
Eiry Roberts - Chief Medical Officer
Kyle Gano - Chief Business Development and Strategy Officer
Todd Tushla - Vice President, Investor Relations
Conference Call Participants
Paul Matteis - Stifel
Tazeen Ahmad - Bank of America
Brian Skorney - Baird
Phil Nadeau - TD Cowen
Brian Abrams - RBC Capital Markets
Stephen - Goldman Sachs
Josh Schimmer - Cantor
Anupam Rama - JP Morgan
Carter Gould - Barclays
Ivy - Jefferies
Jay Olson - Oppenheimer
Rudy Li - Leerink Partners
Myles Minter - William Blair
Neena Bitritto-Garg - Deutsche Bank
Michael Riad - Morgan Stanley
Danielle Brill - Raymond James
Laura Chico - Wedbush Securities
Sumant Kulkarni - Canaccord Genuity
Unknown Analyst - BMO Capital Markets
David Hoang - Citigroup
Mohit Bansal - Wells Fargo
Uy Ear - Mizuho
Schuyler van den Broek - Piper Sandler
Presentation
Operator
Good day and welcome to Neurocrine Biosciences’ year-end and fourth quarter results call.
At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. You may register to ask a question at any time by pressing star, one on your telephone keypad. You may remove yourself by pressing star, two. Please note today’s call will be recorded and I will be standing by if you should need any assistance.
It is now my pleasure to turn the conference over to Todd Tushla, Vice President of Investor Relations. Please go ahead.
Todd Tushla
Thank you, and a good Wednesday morning to everyone. Welcome to Neurocrine Biosciences’ fourth quarter and full year 2023 earnings call.
Joining us today are Kevin Gorman, Chief Executive Officer; Matt Abernethy, Chief Financial Officer; Eiry Roberts, Chief Medical Officer; Eric Benevich, Chief Commercial Officer; and Kyle Gano, Chief Business Development and Strategy Officer.
During the call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings.
Today’s prepared remarks will be a bit longer in duration versus prior earnings calls as we do have a lot of ground to cover. I can assure you that we will do our best to address all of your questions when we get into Q&A....
Neurocrine Biosciences (NBIX) Q4 2023 Earnings Call Transcript